Medical Genetics
2
Archived Theses
0
DOIs Assigned
0%
DOI Rate
Discipline
Assessing the epigenetic modifiers of drug resistance in human astrocyte and glioblastoma co-cultures
Glioblastoma (GBM) is the most common and malignant of all primary CNS tumours. Unfortunately, GBM has very low survival. The standard treatment regimen consists of surgery, ionizing radiation, and chemotherapy. The most common chemotherapeutic used for the treatment of GBM is temozolomide, followed by carmustine, which could not change the overall survival rates in the last 25 years. Unfortunately, most drug trials fail at the initial phases. For this failure in progress, tumour-microenvironment interactions play an important role, beside others causes. Therefore, understanding the nature of therapy resistance in relation to tumour-microenvironment interactions is essential. In this thesis, a new co-culture model was established to examine temozolomide response of tumour cells in the context of astrocyte microenvironment. Contact-dependent and contact-independent co-culture models were examined with cell viability and imaging methods. Contact-dependent astrocyte-U87MG co-cultures presented temozolomide resistance. Transcriptomic differences between U87MG cells alone and in co-cultures with astrocytes were examined by cell sorting, followed by RNA sequencing. As a testament to increased cell-to-cell interaction, co-culture models were found to express high levels of several cell-extracellular matrix interaction pathway components. Specifically, increased levels of collagen (COL), matrix-metalloproteins (MMP), and tubulin (TUB) families were observed. These adaptive changes were most likely vital elements of drug resistance in co-cultures. As contact-dependent temozolomide resistance may involve genetic and epigenetic changes, epigenetic vulnerabilities of tumour cells in co-cultures were examined. Cancers show altered epigenetic regulation; global changes in DNA and histone methylation. Yet, the epigenetic regulation of temozolomide response in co-cultures is not established. We performed a small molecule epigenetic inhibitor probe library screen to examine and identify epigenetic regulators of temozolomide response in co-cultures. We identified several histone demethylase inhibitors, in combination with temozolomide, as potent agents to target U87MG cells cultured with astrocytes. We then focused on GSK-J4, a histone demethylase inhibitor, as a potent agent that could affect GBM cells that are grown in co-cultures. GSK-J4 is a known agent that inhibits KDM6A and KDM6B, whose roles have not been studied in the context of temozolomide response in GBM. To understand the mechanisms of GSK-J4 in co-cultures, cell viability assays with chemical inhibition and CRISPR/Cas9-targeted gene silencing of KDM6A or KDM6B were applied. Further CITE-single cell sequencing was performed in U87MG-astrocyte co-cultures in the presence and absence of GSK-J4. We showed that both cell compartments were differentially represented at their transcriptome levels. Hypoxia and glycolysis-related genes MT-CYB, MT-CO2, MT-ND2, and MTRNR2L10 were upregulated and apoptosis-related genes were down-regulated in both tumour cells and astrocytes in response to GSK-J4. In conclusion, by generating and characterising co-culture models of GBM, we were able to find epigenetic regulators of temozolomide response and present transcriptomic differences that may serve as potential therapeutic intervention points for GBM in the future.
Turboid reveals NEK2a's semi-dynamic cell cycle interactions and Nusap1 as a novel partner
Nek2A is a cell cycle regulated kinase, which is involved in several cellular processes and overexpressed in numerous cancer types. It has been associated with chromosome instability, increased cell proliferation and drug resistance in cancers. Our study primarily aims to identify the specific partners that interact with Nek2A during the cell cycle, deepening our understanding of Nek2's role in cancer. To meet this objective, we employed the TurboID proximity labeling technique on synchronized cell groups, exploring the dynamic interactions of Nek2A as the cell cycle advances. We synchronized the cells using a double thymidine block and harvested them at designated release time points, focusing on G1/S, late S, and G2/M cell cycle phases. Through mass spectrometry, we identified biotinylated proteins, which we further analyzed using MaxQuant, Cassiopeia, and Amica tools. Our experiments reliably identified previously recognized Nek2A partners like the Anaphase Promoting Complex (APC) and Kif24. We confirmed proteins closely interacting with Nek2A during the G1/S, late S, and G2/M stages using western blotting. Co-immunoprecipitation unveiled direct interactions of Nek2A with proteins such as Nusap1, Kif2c, Mapre3, and Mpg. We also confirmed the colocalization of these proteins with Nek2A using fluorescence microscopy. We took a special interest in Nusap1 due to its unique role, distinct from other Nek2A partners. Nusap1 acts as a stabilizer for DNA damage proteins, and its depletion can lead to DNA strand breaks, negatively impacting cell survival. Our analysis highlighted a prevalent occurrence of ubiquitin-driven proteolysis during the cell cycle's progression. We initially studied Nusap1's expression in cells with either diminished or amplified Nek2A activity. Remarkably, there was an increase in Nusap1 levels post-siRNA treatment and in two distinct Nek2 null (KO) cell variants. Conversely, overexpression of Nek2A led to a short-lived reduction in Nusap1 amounts, lasting just 6 hours, before other cell mechanisms presumably balanced it. Using the well- known proteasome inhibitor, MG132, we were able to counteract this reduction. Moreover, we observed a notable reduction in Nusap1 ubiquitination in Nek2A KO cells, pointing to the possible role of proteasomal breakdown processes. A broad protein analysis in Nek2A deficient cells confirmed many proteins, including Nusap1, showed decreased expression. In essence, our findings indicate Nusap1 as a new Nek2A partner, with Nek2A possibly affecting Nusap1's degradation through ubiquitination. The exact nature of this interaction and the clinical significance require further exploration.